Blueprint Medicines (LTS:0HOJ) Capital Expenditure : $-14.58 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Blueprint Medicines Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Blueprint Medicines's cash flow for capital expenditures for the three months ended in Mar. 2024 was $-1.1 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2024 was $-14.58 Mil.

Blueprint Medicines Capital Expenditure Historical Data

The historical data trend for Blueprint Medicines's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Capital Expenditure Chart

Blueprint Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capital Expenditure

Get a 7-Day Free Trial

-14.01

-3.16

-261.24

-8.92

-16.06

Blueprint Medicines Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capital Expenditure	Get a 7-Day Free Trial															-2.58	-2.55	-6.25	-4.67	-1.10

Blueprint Medicines Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.58 Mil.

Blueprint Medicines (LTS:0HOJ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (LTS:0HOJ) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

BPMC:USA 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (LTS:0HOJ) Headlines

No Headlines